Degrees， Temple University School of Medicine / MD (1978)。 Residencies， Temple University School of Medicine / Internal Medicine (1982)。 Fellowships， Johns Hopkins University School of Medicine / Oncology (1987)。
Certifications：
American Board of Internal Medicine / Internal Medicine (1981)；
American Board of Internal Medicine / Medical Oncology (1987)。
The overall goal of Dr. Jones' research is to better understand the biology of normal and abnormal hematopoiesis, with an eye to improving the treatment of blood disorders by translating promising findings to the clinic. A primary area of focus is to identification and biologic characterization of cancer stem cells. It appears that, for most cancers, only a small fraction of the cancer cells retains the capacity to self-renew and proliferate. These characterize the disease. In many tumors, cancer stem cells and their differentiated progeny appear to have markedly different biologic characteristics. Characterizing cancer stem cells has particular relevance for targeted anti-cancer therapies. Therapies that target mature tumor cells may lead to clinical improvement, but are unlikely to be curative unless cancer stem cells are also targeted. Alternatively, relevant targets unique to the rare cancer stem cells may be missed of clinical activity is judged soley by criteria that reflect the effects of treatment on the bulk of the cancer. Thus, understanding the biology of cancer stem cells, especially in relation to their differentiated progeny, is essential for developing effective anticancer treatments. One cancer stem cell specific therapy that appears promising is differentiation therapy. Although self-renewal and differentiation are effectively coupled in normal stem cells, all cancer stem cells show some degree of differentiation block. Re-establishing the differentiation program in cancer stem cells should promote their maturation, leading to a loss of self-renewal capacity.
Selected Publications：
Aksentijevich, I.; Jones, R.J.; Ambinder, R.F.; Garrett-Mayer, E.; Flinn, I.W. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin''s lymphoma. Biol Blood Marrow Transplant. 2006 Sep;12(9):965-972.
Bolanos-Meade, J.; Hartley, E.; Jones, R.J. Long-term follow-up of allogeneic marrow transplantation for acute myelogenous leukemia after treatment with busulfan and cyclophosphamide. Biol Blood Marrow Transplant. 2006 Mar;12(3):366-367.
Brodsky, R.A.; Jones, R.J. Aplastic Anemia. In: Rose, N.R.; Mackay, I.R., editors. 4th ed, The Autoimmune Diseases. Philadelphia, PA: Elsevier; 2006.
Huff, C.A.; Fuchs, E.J.; Smith, B.D.; Blackford, A.; Garrett-Mayer, E.; Brodsky, R.A.; Flinn, I.W.; Ambinder, R.F.; Borrello, I.M.; Matsui, W.H.; Vogelsang, G.B.; Griffin, C.A.; Luznik, L.; Jones, R.J. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant. 2006 Apr;12(4):414-421.
Huff, C.A.; Matsui, W.; Smith, B.D.; Jones, R.J. The paradox of response and survival in cancer therapeutics. Blood. 2006 Jan 15;107(2):431-434.
Huff, C.A.; Matsui, W.H.; Douglas Smith, B.; Jones, R.J. Strategies to eliminate cancer stem cells: clinical implications. Eur J Cancer. 2006 Jun;42(9):1293-1297.